16 January 2024
16 January 2024
The latest approval is based on results from the randomised multicentre Phase IB/III IMscin001 study.
If new treatments are shown to maintain weight loss, they will become game changers.
The approval highlights the safety benefits of AGAMREE in maintaining normal bone metabolism, density and growth versus conventional corticosteroids.
Evencaleucel is the company's most advanced product and is currently undergoing Phase II clinical trials.
Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.
NTX-001 is the only surgical technology designed to prevent Wallerian degeneration.
Disco has built a protein mapping platform for cancer cell surfaces, to unlock targets for the antibody-based therapy market.
The updated binding term sheet for an oral arsenic trioxide therapy sees Phebra take on more duties and BioSenic given royalties.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
